60 Gracechurch Street
London EC3V 0HR
|Mr. Allan John Syms||Exec. Chairman||無||無||1958|
|Dr. Dawn Coverley||Founder, Chief Scientific Officer & Non-Exec. Director||無||無||1967|
|Mr. Nigel R. Lee||Fin. Director & Director||無||無||1963|
|Mr. Morgan Williams||Head of Commercialisation for Yorkshire Cancer Research and Board Observer||無||無||無|
Cizzle Biotechnology Holdings Plc engages in developing a blood test for the early detection of various forms of lung cancer. It develops CIZ1B protein gene and its potential as a diagnostic biomarker for detection and management of lung cancer. The company's CIZ1 promotes DNA replication and its organization and control. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
截至 無 止，Cizzle Biotechnology Holdings Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。